The number of shares and votes in CELLINK AB (publ) have increased as a result of a new issue of 666,028 shares of series B which was carried out as part of the financing for the acquisition of Ginolis Oy. The Board of Directors resolved on an issue in kind on March 1, 2021 in accordance with the authorization from the Extraordinary General Meeting held on December 17, 2020.
Furthermore, the number of shares and votes have increased as a result of a directed new issue of 3,571,429 shares of series B that the Board of Directors resolved on March 11, 2021 in accordance with the authorization from the Extraordinary General Meeting held on December 17, 2020.
Finally, 454,480 warrants were exercised within the CELLINK option program 2018 for new subscription of 454,480 shares of series B.
Through the above-mentioned events, which the Swedish Companies Registration Office registered during March, the number of shares and votes in CELLINK increased by a total of 4,691,937.
As of March 31, 2021, the total number of registered and outstanding shares of CELLINK amounts to 56,293,222, of which 1,500,000 are shares of series A and 54,793,222 are shares of series B, corresponding to a total of 69,793,222 votes. The share capital amounts to SEK 1,407,330.550. The company does not hold any treasury shares.
For further information, please contact:
Gusten Danielsson, CFO CELLINK
Phone (US): +1 (857) 332 2138
Phone (Sweden): +46 709-91 86 04
Email: [email protected]
Isabelle Ljunggren, Head of Communications CELLINK
Phone: +46 708-30 08 90
Email: [email protected]
This is information that CELLINK AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on March 31, 2021, at 08:00 (CEST).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com/investors